1. Microcapsules, characterized in that they contain: a pharmaceutically active substance selected from retinoids； hydrophilic cationic polymer selected from type A gelatins； hydrophilic anionic polymer. 2. Microcapsules according to claim 1, characterized in that they additionally contain a lipophilic medium. Microcapsules according to any one of the preceding paragraphs, characterized in that the retinoid is selected from the group consisting of retinoic acid in trans-trans form or tretinoin, 13-cis-retinoic acid or isotretinoin, acitretin, arotinoic acid, retinol, adapalene, tazarotene, retinaldehyde , etretinate, 3 ′ ′ - tert-butyl-4 ′ - (2-hydroxyethoxy) -4 ′ ′ - pyrrolidin-1-yl- [1,1 ′； 3 ′, 1 ″] - terphenyl-4-carboxylic acid , 2-hydroxy-4- [3-hydroxy-3- (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl) -1-propynyl] benzoic acid or one of its enantiomers, 4 ′ - (4-isopropylaminobu toxins) -3 ′ - (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaft-2-yl) biphenyl-4-carboxylic acid, 4- {3-hydroxy-3- [4- (2-Ethoxyethoxy) -5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaft-2-yl] prop-1-ynyl} benzoic acid or 4- [2- (3-tert-butyl -4-diethylaminophenyl) -2-hydroxyiminoethoxy] -2-hydroxybenzoic acid. 4. The microcapsules of claim 3, wherein the retinoid is 3 ″ - tert-butyl-4 ′ - (2-hydroxyethoxy) -4 ″ - pyrrolidin-1-yl- [1,1 ′； 3 ′, 1 ′ ′] -Terphenyl-4-carboxylic acid or is adaptal and preferably 3 ′ ′ - tert-butyl-4 ′ - (2-hydroxyethoxy) -4 ′ ′ - pyrrolidin-1-yl- [1,1 ′； 3 ′, 1 ′ ′] - terphenyl-4-carboxylic acid. 5. Microcapsules according to any one of paragraphs. 1, 2 and 4, characterized in that the hydrophilic anionic polymer is a gum arabic. 6. Microcapsules according to any one of paragraphs. 1, 2 and 4, characterized in that the pharmaceutically active substance is encapsulated directly in the solid state or dispersed in a lipophilic medium, and1. Микрокапсулы, отличающиеся тем, что они содержат:фармацевтически активное вещество, выбранное из ретиноидов； гидрофильный катиона
